Table 2 Univariate analysis of locoregional recurrence-free survival (LRFS), relapse-free survival (RFS), and overall survival (OS) in patients with (i) T2-3N0M0 and (ii) T2-3N1-2M0 stage disease.

Gender

Male

77.3 (62.2–92.4)

0.970

73.4 (58.3–88.5)

0.943

72.1 (56.4–87.8)

0.382

49.3 (30.5–68.1)

0.793

37.4 (20.9–53.9)

0.297

42.3 (25.2–59.4)

0.340

Female

78.7 (64.6–92.8)

72.1 (56.4–87.8)

81.2 (67.5–94.9)

46.6 (31.5–61.7)

26.4 (13.7–39.1)

29.7 (16.4–43.0)

Age (years)

≤60

78.2 (59.2–97.2)

0.810

72.9 (52.5–93.2)

0.757

89.5 (75.8–103.2)

0.113

52.5 (33.7–71.3)

0.456

39.3 (21.3–57.3)

0.184

42.1 (23.5–60.7)

0.056

>60

78.1 (65.9–90.3)

72.8 (60.1–85.5)

71.4 (58.1–84.7)

44.8 (30.3–59.3)

26.1 (13.9–38.3)

31.1 (18.4–43.8)

Tumor size^* (cm)

≤3

91.2 (81.8–100.6)

0.018

85.2 (73.2–97.2)

0.021

88.3 (77.5–99.1)

0.060

55.6 (38.4–72.8)

0.083

34.5 (19.2–49.8)

0.425

41.7 (25.8–57.6)

0.375

>3

62.9 (45.1–80.7)

58.8 (41.4–76.2)

64.3 (47.1–81.5)

40.8 (25.7–55.9)

27.9 (14.5–41.2))

28.4 (14.5–42.3)

T classification

T2

93.3 (86.0–100.6)

<0.001

87.1 (77.5–96.7)

<0.001

86.8 (76.8–96.8)

<0.001

56.3 (40.4–72.2)

0.099

39.6 (24.5–54.7)

0.074

43.5 (28.2–58.7)

0.086

T3

34.6 (10.5–58.7)

33.3 (11.5–55.1)

48.6 (24.9–72.3)

38.9 (22.8–55.0)

21.8 (8.9–34.7)

25.4 (11.5–39.3)

N classification

N1

—

—

—

—

—

—

54.6 (40.9–68.3)

0.002

36.0 (23.3–48.7)

0.002

42.0 (28.9–55.1)

<0.001

N2

—

—

—

32.9 (13.5–52.3)

19.2 (3.3–35.1)

18.0 (2.3–33.7)

Preop CA 19-9 level

≤37

86.7 (77.5–95.9)

<0.001

81.4 (70.8–92.0)

<0.001

80.7 (69.7–91.7)

0.049

55.2 (40.9–69.5)

0.003

35.2 (22.3–48.1)

0.020

41.4 (27.9–54.9)

0.104

(U/mL)

>37

35. 0 (4.8–65.2)

30.0 (2.6–57.4)

56.2 (27.2–85.2)

32.1 (14.1–50.1)

22.2 (6.5–37.9)

22.2 (6.5–37.9)

Postop CA 19-9 level

≤37

82.4 (72.4–92.3)

0.001

78 (67.4–88.6)

0.001

80.8 (70.4–91.2)

0.009

54.9 (41.8–68.0)

<0.001

38.5 (26.0–51.0)

<0.001

42.4 (29.9–54.9)

0.001

(U/mL)

>37

^†28.6 (−15.1–72.3)

^†19.0 (−13.9–51.9)

35.7 (−3.1–74.5)

23.7 (3.1–44.3)

5.3 (−4.7–15.3)

10.5 (−3.2–24.2)

Histologic

WD/MD

81.8 (70.2–93.4)

0.222

76.2 (60.7–91.7)

0.272

80.1 (68.3–91.9)

0.410

53.0 (38.9–67.1)

0.181

36.3 (22.8–49.8)

0.119

40.3 (26.4–54.2)

0.159

differentiation

PD

67.5 (45.9–89.1)

63.2 (41.4–85.0)

67.7 (46.3–89.1)

38.6 (19.6–57.6)

22.1 (7.2–37.0)

25.8 (10.3–41.2)

Resection margin

Negative

78.9 (68.7–89.1)

0.522

73.2 (62.2–84.2)

0.579

77.7 (67.3–88.1)

0.467

48.0 (35.7–60.3)

0.848

31.6 (21.2–42.0)

0.243

34.9 (24.3–45.4)

0.837

Close

^‡50.0 (−19.4–119.4)

^‡66.7 (13.3–120)

0 (-)

^†50.0 (−19.4–119.4)

^†0 (−)

^†50 (−19.4–119.4)

Vascular invasion

No

83.5 (73.5–93.5)

<0.001

78.7 (67.9–89.5)

<0.001

83.8 (74.0–93.6)

<0.001

64.7 (49.2–80.2)

0.002

51.4 (35.1–67.7)

<0.001

58.8 (42.7–74.9)

<0.001

Yes

^†37.0 (0.3–73.4)

^†33.3 (2.5–64.1)

^†26.7 (−4.5–57.9)

30.2 (14.5–45.9)

13.0 (2.8–23.2)

12 (2.2–21.8)

Lymphatic invasion

No

87.3 (76.9–97.7)

0.002

82.9 (71.4–94.5)

0.001

89.8 (80.2–99.4)

<0.001

82.2 (64.0–100.4)

0.004

60.2 (37.3–83.1)

0.005

59.3 (36.0–82.6)

0.042

Yes

62.0 (42.2–81.8)

54.7 (34.9–74.5)

53.3 (32.5–74.1)

37.5 (24.8–50.2)

22.4 (12.0–32.8)

27.9 (16.5–39.3)

Perineural invasion

No

90.6 (81.8–99.4)

0.001

85.7 (75.1–96.3)

0.001

90.5 (81.7–99.3)

0.001

65.2 (47.6–82.8)

0.026

45.7 (27.7–63.7)

0.017

51.6 (33.4–69.8)

0.023

Yes

53.1 (31.1–75.1)

48.2 (27.4–69.0)

51.2 (29.6–72.8)

36.2 (21.9–50.5)

22.4 (10.8–34.0)

25.1 (12.9–37.3)

Adjuvant Therapy

No-AT

79.0 (64.1–93.9)

0.354

73.2 (57.3–89.1)

0.670

74.8 (58.3–91.3)

0.849

19.0 (1.8–36.2)

<0.001

11.6 (−2.3–25.5)

<0.001

4.3 (−4.1–12.7)

<0.001

CTx

65.0 (40.1–89.9)

65.5 (40.8–90.2)

73.3 (51.0–95.6)

26.8 (8.6–45.0)

16.7 (1.8–31.6)

22.7 (5.4–39.9)

CRT

86.2 (71.7–100.7)

75.0 (55.0–95.0)

81.1 (63.9–98.3)

82.1 (67.8–96.4)

53.3 (36.4–70.2)

64 (47.5–80.5)